gamma-Aminobutyric acid

The MIND diet slowed cognitive decline in older adults, but varied with lifestyle and vascular factors. Genetic effects on brain volumes were identified in ADHD and Parkinson's. AAV-GAD gene therapy showed safety and motor improvement in a Parkinson's trial. CVN424 reduced 'off' time in Parkinson's. A tool predicts epilepsy risk after cerebral venous sinus thrombosis. Experts identified eight headache research priorities. Modafinil and cognitive behavioral therapy had similar effects on MS fatigue. Anti-tumor necrosis factor therapy increased risk of inflammatory CNS diseases. Mailed educational interventions failed to reduce inappropriate prescribing in Alzheimer's and dementia.

MeiraGTx's gene therapy (AAV-GAD) for Parkinson’s disease passed midphase trial, showing significant improvement in PDQ-39 scores at 26 weeks with high-dose treatment, and is now in discussion for Phase III. AAV-GAD was safe and well-tolerated, with no SAEs related to treatment.

MeiraGTx's AAV-GAD gene therapy for Parkinson's disease showed significant safety and efficacy in a small phase 1/2 study, prompting plans for a pivotal trial. The therapy, administered via subthalamic nucleus infusion, demonstrated clinically meaningful improvements in motor function and quality of life scores.

References discuss addiction as a brain disease, neuroimaging findings in cocaine dependence, and mindfulness-based treatments for addiction, among other topics.

Diamyd Medical aims for Accelerated Market Approval for its precision medicine for autoimmune diabetes. Key events include positive FDA feedback on potential Accelerated Approval for Diamyd® in Type 1 Diabetes, securing second U.S. FDA Fast Track designation, and positive interim analysis results for Phase 3 Trial DIAGNODE-3. The company plans to pursue an accelerated approval pathway for Diamyd®, with an interim readout expected in March 2026.

Today is the last day of trading for Diamyd Medical's TO 3 warrants, with an exercise period until September 30, 2024. Two warrants entitle holders to subscribe for one new share at SEK 11.00 each. Board members and CEO intend to exercise warrants worth SEK 5.1 million. Diamyd Medical received SEK 17.5 million in milestone payments and aims for an early readout from the DIAGNODE-3 trial in March 2026.

Obesity is a global epidemic with significant health risks. Recent advances in medical weight management include FDA-approved drugs like Metreleptin, Setmelanotide, and others targeting non-syndromic obesity. These medications, including orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide, and semaglutide, act to reduce appetite and increase satiety, improving weight and metabolic parameters. Tirzepatide, a promising drug, is under FDA review. The future of obesity treatment may lie in precision medicine and novel drugs with potent mechanisms of action.